Zoetis Inc. which can be found using ticker (ZTS) have now 12 confirmed analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price High/Low ranges between 260 and 180 suggesting an average Analsyt target price of $215.75. Given that the stocks previous close was at $173.54 this would imply there is now a potential upside of 24.3%. Also worth taking note is the 50 day moving average now sits at $167.01 and the 200 day MA is $160.30. The total market capitalization for the company now stands at $80,763m. Find out more information at: https://www.zoetis.com
The potential market cap would be $100,407m based on the market consensus.
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. The company also offers parasiticides; vaccines; anti-infectives; other pharmaceutical products; dermatology; and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products and laboratory; and other non-pharmaceutical products. It markets its products to veterinarians, livestock producers, and pet owners. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
The company has a dividend yield of 0.86% with the ex dividend date set at 20-4-2023 (DMY).
Other points of data to note are a P/E ratio of 38.89, revenue per share of 17.23 and a 12.73% return on assets.
